TITLE

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

AUTHOR(S)
Aronne, L. J.; Tonstad, S.; Moreno, M.; Gantz, I.; Erondu, N.; Suryawanshi, S.; Molony, C.; Sieberts, S.; Nayee, J.; Meehan, A. G.; Shapiro, D.; Heymsfield, S. B.; Kaufman, K. D.; Amatruda, J. M.
PUB. DATE
May 2010
SOURCE
International Journal of Obesity;May2010, Vol. 34 Issue 5, p919
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective:To evaluate the efficacy, safety and tolerability of taranabant in obese and overweight patients.Design:Double-blind, randomized, placebo-controlled study.Subjects:Patients were 18 years old, with body mass index of 27–43 kg m–2, and 51% with metabolic syndrome (MS) randomized to placebo (N=417) or taranabant 2 mg (N=414), 4 mg (N=415) or 6 mg (N=1256) for 104 weeks.Measurements:Key efficacy measurements included body weight, waist circumference (WC), lipid and glycemic end points.Results:On the basis of risk/benefit assessments, the 6-mg dose was discontinued during year 1 (patients on 6 mg were down-dosed to 2 mg or placebo) and the 4-mg dose was discontinued during year 2 (patients on 4 mg were down-dosed to 2 mg). Changes from baseline in body weight at week 52 (all-patients-treated population, last observation carried forward analysis) were −2.6, −6.6 and −8.1 kg, respectively, for placebo and taranabant 2 and 4 mg (both doses P<0.001 vs placebo). For patients who completed year 1, changes from baseline in body weight at week 104 were −1.4, −6.4 and −7.6 kg for placebo and taranabant 2 and 4 mg, respectively (both doses P<0.001 vs placebo). The proportions of patients at weeks 52 and 104 who lost at least 5 and 10% of their baseline body weight were significantly higher and the proportions of patients who met criteria for MS were significantly lower for taranabant 2 and 4 mg vs placebo. The incidence of adverse experiences classified in the gastrointestinal, nervous, psychiatric, cutaneous and vascular organ systems were generally observed to be dose related with taranabant vs placebo.Conclusion:Taranabant at the 2- and 4-mg dose was effective in achieving clinically significant weight loss over 2 years and was associated with dose-related increases in adverse experiences. On the basis of these and other data, an assessment was made that the overall safety and efficacy profile of taranabant did not support its further development for the treatment of obesity.
ACCESSION #
50336268

 

Related Articles

  • Phone and e-mail counselling are effective for weight management in an overweight working population: a randomized controlled trial. van Wier, Marieke F.; Ariëns, Geertje A. M.; Dekkers, J. Caroline; Hendriksen, Ingrid J. M.; Smid, Tjabe; van Mechelen, Willem // BMC Public Health;2009, Vol. 9 Issue 1, p1 

    Background: The work setting provides an opportunity to introduce overweight (i.e., Body Mass Index ≥ 25 kg/ m2) adults to a weight management programme, but new approaches are needed in this setting. The main purpose of this study was to investigate the effectiveness of lifestyle...

  • Effectiveness of strategies for recruiting overweight and obese Generation Y women to a clinical weight management trial. Griffin, Hayley J.; O'Connor, Helen T.; Rooney, Kieron B.; Steinbeck, Katharine S. // Asia Pacific Journal of Clinical Nutrition;Jun2013, Vol. 22 Issue 2, p235 

    Aim: Limited research in young overweight and obese women indicates that they are difficult to recruit to weight management trials, with attrition higher and weight loss success lower than middle to older age participants. This study aimed to evaluate the effectiveness of different recruitment...

  • A Pooled Analysis of Body Mass Index and Mortality among African Americans. Cohen, Sarah S.; Park, Yikyung; Signorello, Lisa B.; Patel, Alpa V.; Boggs, Deborah A.; Kolonel, Laurence N.; Kitahara, Cari M.; Knutsen, Synnove F.; Gillanders, Elizabeth; Monroe, Kristine R.; de Gonzalez, Amy Berrington; Bethea, Traci N.; Black, Amanda; Fraser, Gary; Gapstur, Susan; Hartge, Patricia; Matthews, Charles E.; Park, Song-Yi; Purdue, Mark P.; Singh, Pramil // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Pooled analyses among whites and East Asians have demonstrated positive associations between all-cause mortality and body mass index (BMI), but studies of African Americans have yielded less consistent results. We examined the association between BMI and all-cause mortality in a sample of...

  • Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients. Richelsen, Bjørn; Tonstad, Serena; Rössner, Stephan; Toubro, Søren; Niskanen, Leo; Madsbad, Steen; Mustajoki, Pertti; Rissanen, Aila // Diabetes Care;Jan2007, Vol. 30 Issue 1, p27 

    OBJECTIVE -- To investigate the efficacy of orlistat on the maintenance of weight loss over 3 years following a major weight loss induced by very-low-energy diet (VLED) in obese patients with metabolic risk factors such as dyslipidemia, impaired fasting glucose, and diet-treated type 2 diabetes....

  • Desenvolvimento do arco plantar na inf�ncia e adolesc�ncia: an�lise plantar em escolas p�blicas. Minghelli, Beatriz; Marreiros, Nuno; Valente, Filipe; Ribeiro, Tatiana; Andrez, Teresa; Varela, Edna; Felizardo, Rodrigo // Sa�de & Tecnologia;2011, Issue 5, p5 

    The plantar arch is being developed in the first years of children's life and there are many factors that can influence this formation such as age, gender and overweight. The aim of this study was to examine the development of plantar arch in children and adolescents checking the prevalence of...

  • The change in weight perception of weight status among the overweight: comparison of NHANES III (1988-1994) and 1999-2004 NHANES. Johnson-Taylor, Wendy L.; Fisher, Rachel A.; Hubbard, Van S.; Starke-Reed, Pamela; Eggers, Paul S. // International Journal of Behavioral Nutrition & Physical Activit;2008, Vol. 5, Special section p1 

    Objectives: This study seeks to determine whether perception of weight status among the overweight has changed with the increasing overweight/obesity prevalence. Methods: The perception of weight status was compared between overweight participants (BMI between 25.0-29.9 kg/m²) from NHANES III...

  • BMI Flawed. Toops, Diane // Food Processing (00156523);Oct2006 Supplement, Vol. 67, p5 

    The article reports on a study which showed that body mass index (BMI) is badly flawed as a standard measure of obesity. Doctors at the Mayo Clinic College of Medicine in Rochester, Minnesota reviewed data from 40 studies covering 250,000 people with heart disease. They found that patients with...

  • WALKING FOR WEIGHT LOSS? READ THIS. Bodnar, Sara // Shape;Jan2008, Vol. 27 Issue 5, p95 

    The article offers information regarding a study on walking for weight loss. The study conducted by Raymond C. Browning, instructor at the University of Colorado's Center for Human Nutrition suggests overweight people to walk slow in the beginning of their exercise session. It states that while...

  • Modifiable environmental influences on body mass index shared by young adult brothers. Rokholm, B; Silventoinen, K; Tynelius, P; Sørensen, T I A; Rasmussen, F // International Journal of Obesity;Feb2013, Vol. 37 Issue 2, p211 

    OBJECTIVES:Twin and adoption studies suggest that family environment has little, if any, influence on body mass index (BMI) in adulthood. We investigated the hypothesis that the differences in the years of birth between siblings influence their similarity in BMI at comparable ages, which would...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics